314 related articles for article (PubMed ID: 17885557)
1. A possible association between primary aldosteronism and a lower beta-cell function.
Mosso LM; Carvajal CA; Maiz A; Ortiz EH; Castillo CR; Artigas RA; Fardella CE
J Hypertens; 2007 Oct; 25(10):2125-30. PubMed ID: 17885557
[TBL] [Abstract][Full Text] [Related]
2. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
[TBL] [Abstract][Full Text] [Related]
3. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
4. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment.
Sindelka G; Widimský J; Haas T; Prázný M; Hilgertová J; Skrha J
Exp Clin Endocrinol Diabetes; 2000; 108(1):21-5. PubMed ID: 10768828
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.
Seiler L; Rump LC; Schulte-Mönting J; Slawik M; Borm K; Pavenstädt H; Beuschlein F; Reincke M
Eur J Endocrinol; 2004 Mar; 150(3):329-37. PubMed ID: 15012618
[TBL] [Abstract][Full Text] [Related]
7. Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.
Carvajal CA; Herrada AA; Castillo CR; Contreras FJ; Stehr CB; Mosso LM; Kalergis AM; Fardella CE
J Endocrinol Invest; 2009 Oct; 32(9):759-65. PubMed ID: 19605974
[TBL] [Abstract][Full Text] [Related]
8. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity.
Haluzík M; Sindelka G; Widimský J; Prázný M; Zelinka T; Skrha J
J Hum Hypertens; 2002 Jan; 16(1):41-5. PubMed ID: 11840228
[TBL] [Abstract][Full Text] [Related]
9. [Comparison on metabolic disorders and uric acid levels between patients with primary aldosteronism and essential hypertension].
Deng YJ; Zhang SL; Liu PM; Mai LF; Tang JY; Yan L
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Sep; 44(9):743-749. PubMed ID: 27667270
[No Abstract] [Full Text] [Related]
10. Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans.
Adler GK; Murray GR; Turcu AF; Nian H; Yu C; Solorzano CC; Manning R; Peng D; Luther JM
Hypertension; 2020 May; 75(5):1251-1259. PubMed ID: 32172621
[TBL] [Abstract][Full Text] [Related]
11. [The application of captopril challenge test in the diagnosis of primary aldosteronism].
Chen S; Zeng ZP; Song AL; Zhu L; Lu L; Tong AL; Shi C; Li HZ
Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):402-408. PubMed ID: 28592038
[No Abstract] [Full Text] [Related]
12. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
[TBL] [Abstract][Full Text] [Related]
13. Insulin sensitivity in patients with primary aldosteronism: a follow-up study.
Catena C; Lapenna R; Baroselli S; Nadalini E; Colussi G; Novello M; Favret G; Melis A; Cavarape A; Sechi LA
J Clin Endocrinol Metab; 2006 Sep; 91(9):3457-63. PubMed ID: 16822818
[TBL] [Abstract][Full Text] [Related]
14. Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications.
Tomaschitz A; Piecha G; Ritz E; Meinitzer A; Haas J; Pieske B; Wiecek A; Rus-Machan J; Toplak H; März W; Verheyen N; Gaksch M; Amrein K; Kraigher-Krainer E; Fahrleitner-Pammer A; Pilz S
Clin Exp Hypertens; 2015; 37(2):108-15. PubMed ID: 24785704
[TBL] [Abstract][Full Text] [Related]
15. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism.
Fischer E; Adolf C; Pallauf A; Then C; Bidlingmaier M; Beuschlein F; Seissler J; Reincke M
J Clin Endocrinol Metab; 2013 Jun; 98(6):2513-20. PubMed ID: 23539730
[TBL] [Abstract][Full Text] [Related]
17. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients.
Colussi G; Catena C; Lapenna R; Nadalini E; Chiuch A; Sechi LA
Diabetes Care; 2007 Sep; 30(9):2349-54. PubMed ID: 17575088
[TBL] [Abstract][Full Text] [Related]
19. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.
Fardella CE; Mosso L; Gómez-Sánchez C; Cortés P; Soto J; Gómez L; Pinto M; Huete A; Oestreicher E; Foradori A; Montero J
J Clin Endocrinol Metab; 2000 May; 85(5):1863-7. PubMed ID: 10843166
[TBL] [Abstract][Full Text] [Related]
20. Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism.
Zhang SL; Gao JW; Guo Y; Feng QL; Tang JY; Yan L; Wang JF; Cheng H; Liu PM
Front Endocrinol (Lausanne); 2020; 11():547356. PubMed ID: 33101195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
